In vjcitn/YESCDS: Cancer data science activities for CZI YES for CURE collaboration

suppressMessages({
 suppressPackageStartupMessages({
  library(YESCDS)
library(tibble)
library(dplyr)
library(plotly)
library(ggplot2)
library(ggbeeswarm)
library(DT)
data(woncan_meta)
data(woncan)
littab = woncan |> select(MSA, `Cancer Sites`, Age.Adjusted.Rate) |> as.data.frame()
  })
 })

Equipoise: individual and clinical

Distinguished in AMA ethics, 2015

What is the state of medical knowledge? Why is this trial asking an important question? How does the likelihood of benefiting in study A compare with that of benefiting in study B or with the standard of care? -- attributed to B. Freedman

• Belief in the new treatment

• Belief in the patient's suitability for the new treatment

• Interpretation of new evidence

• Risk that new evidence will "regress"

• Alternative: fully informed patient consent

Discussion Questions

D.2.1

vjcitn/YESCDS documentation built on April 16, 2024, 1:03 p.m.